GlassScriptPhysician profile
Monte S Meltzer
NPI 1861418840
$220,399.92
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $28K · 2021: $30K · 2022: $26K · 2023: $710 · 2024: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $173,474.76 | 2019-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $44,552.54 | 2019-2024 | |
| Janssen Biotech, INC. | $365.43 | 2019-2023 | Tremfya |
| Abbvie INC. | $354.67 | 2020-2024 | |
| Leo Pharma INC. | $247.64 | 2021-2023 | Adbry |
| Sun Pharmaceutical Industries INC. | $233.85 | 2019-2023 | Absorica Ld, Winlevi |
| Incyte Corporation | $208.16 | 2021-2022 | |
| Ucb, INC. | $172.63 | 2021-2023 | Cimzia |
| Genzyme Corporation | $132.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.58 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $101.65 | 2021-2024 | Dupixent, Libtayo |
| Celgene Corporation | $91.00 | 2019 | |
| Galderma Laboratories, L.P. | $58.71 | 2022-2023 | Epsolay, Aklief, Twyneo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.18 | 2022-2023 | Arazlo |
| Sebela Pharmaceuticals INC. | $43.87 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $40.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Janssen Scientific Affairs, LLC | $32.30 | 2020 | |
| Arcutis Biotherapeutics, INC. | $24.17 | 2023 | |
| Vyne Pharmaceuticals INC. | $20.80 | 2020 | |
| Dermavant Sciences, INC. | $18.64 | 2023 | Vtama |
| Amgen INC. | $18.50 | 2023 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Meltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.